timbetasin ophthalmic (RGN-259) / ReGenTree, RegeneRx  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
timbetasin ophthalmic (RGN-259) / ReGenTree
ARISE-2, NCT02974907: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome :

Checkmark ARISE-2
Oct 2017 - Dec 2017: ARISE-2
Checkmark ARISE-2 trial in moderate-to-severe dry eye disease
Oct 2017 - Oct 2017: ARISE-2 trial in moderate-to-severe dry eye disease
Completed
3
601
US
RGN-259, Tβ4, Thymosin Beta 4, Placebo, Vehicle Control
ReGenTree, LLC
Dry Eye Syndrome
09/17
03/18
SEER-1, NCT02600429: Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy :

Terminated
3
18
US
RGN-259, Tβ4, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
11/19
03/20
ARISE-3, NCT03937882: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome:

Hourglass Dec 2020 - Dec 2020 : Efficacy data from P3 ASPIRE-3 trial in US for dry eye syndrome
Hourglass Nov 2020 - Nov 2020 : Completion of P3 ARISE-3 trial in US for dry eye syndrome
Completed
3
700
US
RGN-259, Tβ4, Thymosin Beta 4, Placebo, Vehicle Control
ReGenTree, LLC
Dry Eye Syndromes, Dry Eye
11/20
10/21
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24
ARISE-1, NCT02597803: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome:

Checkmark P2b/3 trial data in dry eye
May 2016 - May 2016: P2b/3 trial data in dry eye
Completed
2/3
317
US
RGN-259, Tβ4, Thymosin Beta 4, Placebo, Vehicle Control
ReGenTree, LLC
Dry Eye Syndrome
06/16
07/16

Download Options